Investigating the Antiproliferative and Antioxidant Properties of Pancratium maritimum L. (Amaryllidaceae) Stems, Flowers, Bulbs, and Fruits Extracts
Table 2
Antiproliferative capacity [IC50 (g/mL)] of P. maritimum extracts.
P. maritimum
MCF-7
HeLa
MDA-MB-231
C32
A549
LNCaP
PC3
Flowers
ETP
156.3 ± 6.1
175.1 ± 5.4
NA
89.5 ± 3.8
100.2 ± 3.7
98.4 ± 4.4
171.5 ± 5.7
ET1
78.7 ± 3.4
80.8 ± 3.9
134.6 ± 4.3
67.2 ± 2.9
81.3 ± 3.1
75.8 ± 3.5
119.6 ± 4.0
AQ
141.7 ± 4.3
134.7 ± 3.8
NA
179.8 ± 5.4
112.2 ± 3.8
85.5 ± 3.5
176.7 ± 3.9
ET2
176.2 ± 4.3
198.7 ± 3.5
NA
172.1 ± 2.8
100.1 ± 1.8
85.5 ± 3.5
176.7 ± 3.9
Fruits
ETP
171.6 ± 5.3
132.9 ± 3.3
NA
79.2 ± 3.4
123.1 ± 3.7
79.6 ± 3.2
143.7 ± 3.8
ET1
45.2 ± 3.1
36.9 ± 3.4
144.9 ± 4.4
61.0 ± 3.9
80.5 ± 3.9
77.9 ± 3.7
121.3 ± 4.4
AQ
36.5 ± 3.7
49.9 ± 3.2
185.4 ± 2.9
65.2 ± 3.7
82.6 ± 4.0
65.3 ± 3.8
128.4 ± 4.6
ET2
44.3 ± 3.9
42.7 ± 3.8
155.7 ± 3.9
58.4 ± 3.8
122.7 ± 4.6
46.8 ± 4.2
110.3 ± 2.7
Stems
ETP
122.8 ± 5.8
135.2 ± 6.1
NA
71.1 ± 3.0
85.3 ± 3.5
70.6 ± 3.4
129.9 ± 4.8
ET1
56.2 ± 3.4
50.1 ± 3.2
NA
27.1 ± 3.5
59.4 ± 3.5
70.1 ± 3.2
178.2 ± 3.3
AQ
132.1 ± 2.2
NA
176.3 ± 5.6
188.6 ± 3.4
192.1 ± 4.9
88.2 ± 3.1
100.3 ± 2.6
ET2
183.5 ± 5.4
NA
NA
187.2 ± 3.5
123.4 ± 5.9
178.9 ± 4.3
173.9 ± 5.1
Bulbs
ETP
45.9 ± 3.2
40.8 ± 4.9
111.7 ± 4.1
34.7 ± 3.9
76.3 ± 3.6
66.1 ± 3.2
80.2 ± 4.0
ET1
NA
186.5 ± 5.48
NA
125.7 ± 4.8
187.1 ± 4.7
167.2 ± 5.4
179.1 ± 5.5
AQ
182.5 ± 5.4
178.9 ± 4.3
NA
182.9 ± 3.9
182.5 ± 5.4
178.9 ± 4.3
176.3 ± 5.6
ET2
138.6 ± 2.2
NA
144.2 ± 2.8
181.2 ± 3.6
190.3 ± 4.1
75.3 ± 3.3
102.3 ± 2.8
Positive control
Vinblastine
45.5 ± 1.9
67.3 ± 2.0
29.3 ± 0.9
Doxorubicin
4.04 ± 0.4
3.6 ± 0.3
14.9 ± 1.4
1.5 ± 0.1
Taxol
0.08 ± 0.006
0.011 ± 0.008
8.62 ± 0.6
2.3 ± 0.4
Data are expressed as mean ± standard deviation (SD) (n= 3). ETP: petroleum ether extract; ET1: sequential extraction with ethanol; AQ: sequential extraction with water; ET2: maceration with ethanol; MCF-7: human Caucasian breast carcinoma HeLa: Human cervix epithelioid carcinoma; MDA-MB-231: human Caucasian breast adenocarcinoma; C32: amelanotic melanoma; A549: lung carcinoma; LNCaP: human Caucasian prostate carcinoma; PC3: human Caucasian prostate adenocarcinoma. MCF-7, HeLa, and MDA-MB-231: one-way ANOVA p <0.0001 followed by multicomparison Dunnett’s test: p <0.01 compared with doxorubicin. C32, A549, and LNCaP: one-way ANOVA p <0.0001 followed by multicomparison Dunnett’s test: p <0.01 compared with vinblastine.
